Asset Details
Do you wish to reserve the book?
Perioperative High-Dose-Rate Brachytherapy in the Treatment of Recurrent Malignant Gliomas
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Perioperative High-Dose-Rate Brachytherapy in the Treatment of Recurrent Malignant Gliomas
Do you wish to request the book?
Perioperative High-Dose-Rate Brachytherapy in the Treatment of Recurrent Malignant Gliomas
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Perioperative High-Dose-Rate Brachytherapy in the Treatment of Recurrent Malignant Gliomas
2009
Overview
Purpose:
To assess the feasibility and effectiveness of perioperative high-dose-rate brachytherapy for recurrent malignant gliomas.
Patients and Methods:
Between 2005 and 2008, 21 patients (14 males and seven females) with relapsed malignant glioma underwent a second surgery followed by a brachytherapy implant in the surgical cavity. Median age was 60 years, and median Karnofsky performance status 80. A single fraction of 18 Gy specified at 5 mm depth was administered perioperatively. Then, the applicator was removed nonsurgically. Mean postoperative hospitalization time was 3 days.
Results:
At the time of analysis, 15 patients (71%) had died and six (29%) were alive. Median follow-up was 32.3 months. Median overall survival from diagnosis amounted to 21.7 months. Median survival after recurrence was 8.0 months, and 6-month progression-free survival 42%. Patients were stratified into classes according to the prognostic recursive partitioning analysis.
Conclusion:
Perioperative brachytherapy has proven to be safe and well tolerated in patients with recurrent malignant glioma. No severe toxicity was reported, and the treatment has proven to be effective in symptomatic recurrences of malignant gliomas.
Publisher
Urban and Vogel,Springer Nature B.V
Subject
/ Aged
/ Antineoplastic Agents, Alkylating - therapeutic use
/ Brachytherapy - instrumentation
/ Brain Neoplasms - drug therapy
/ Brain Neoplasms - radiotherapy
/ Dacarbazine - analogs & derivatives
/ Dacarbazine - therapeutic use
/ Female
/ Humans
/ Male
/ Medicine
/ Neoplasm Recurrence, Local - mortality
/ Neoplasm Recurrence, Local - radiotherapy
/ Neoplasm Recurrence, Local - surgery
/ Oncology
